fda warning bpc-157 unapproved drug marketing warning letter issued its first to a dispenser (a medical spa) for violating the Supply Chain Security Act (DSCSA), including failing to source products from authorized trading partners and… FDA is moving to restrict
FDA is moving to restrict mass marketed compounded GLP 1 products that aren't FDA approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified FDA Sends Warning Letters to More Than 50 GLP 1 Compounders and Manufacturers Wilson Sonsini Unregulated Peptide Use in the Age of Biohacking: Digital Promotion, Gray Market Access, and Emerging Public Health Risks Cureus CNN) An FDA advisory committee meeting this week will consider whether several non FDA approved peptide injections should be allowed into compounding pharmacies via the 503A Bulk List, with FDA staff so far
Pay in 4 interest-free payments of $6.96 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22

